Who are Mupirocin Ointment [Treatment]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intranasal Mupirocin and Topical Chlorhexidine, BACTROBAN® Nasal ong, Chlorhexidine, Mupirocin, Mupirocin + Chlorhexidin, mupirocin 2% ointment, Benzoyl peroxide with clindamycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mupirocin-ointment-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Mupirocin Ointment [Treatment] — Competitive Intelligence Brief

Mupirocin Ointment [Treatment] (Mupirocin Ointment [Treatment]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic. Area: Infectious Disease / Dermatology.

marketed Topical antibiotic Isoleucyl-tRNA synthetase Infectious Disease / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Mupirocin Ointment [Treatment] (Mupirocin Ointment [Treatment]) — US Department of Veterans Affairs. Mupirocin inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase, preventing bacterial growth and reproduction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mupirocin Ointment [Treatment] TARGET	Mupirocin Ointment [Treatment]	US Department of Veterans Affairs	marketed	Topical antibiotic	Isoleucyl-tRNA synthetase
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
BACTROBAN® Nasal ong	BACTROBAN® Nasal ong	Lindenhofgruppe AG	marketed	Topical antibiotic	Isoleucyl-tRNA synthetase
Chlorhexidine, Mupirocin	Chlorhexidine, Mupirocin	University of Tennessee	marketed	Topical antimicrobial combination	Bacterial cell membrane (chlorhexidine); isoleucyl-tRNA synthetase (mupirocin)
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
mupirocin 2% ointment	mupirocin 2% ointment	Philippine Dermatological Society	phase 3	bacterial protein synthesis inhibitor	isoleucyl-tRNA synthetase
Benzoyl peroxide with clindamycin	Benzoyl peroxide with clindamycin	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic class)

Lindenhofgruppe AG · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mupirocin Ointment [Treatment] — Competitive Intelligence Brief. https://druglandscape.com/ci/mupirocin-ointment-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab